Cover Image
市場調查報告書

皮黴菌病:開發中產品分析

Dermatomycoses - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 361628
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
皮黴菌病:開發中產品分析 Dermatomycoses - Pipeline Review, H2 2016
出版日期: 2016年11月30日 內容資訊: 英文 61 Pages
簡介

本報告提供皮黴菌病的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

皮黴菌病概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

皮黴菌病:企業開發中的治療藥

皮黴菌病:大學/機關研究中的治療藥

皮黴菌病:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

皮黴菌病:企業開發中的產品

皮黴菌病:大學/機關研究中的產品

皮黴菌病的治療藥開發企業

  • Anacor Pharmaceuticals, Inc.
  • Blueberry Therapeutics Ltd
  • Daewoong Pharmaceutical Co., Ltd.
  • Helix BioMedix, Inc.
  • TGV-Laboratories
  • Viamet Pharmaceuticals, Inc.

皮黴菌病:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

皮黴菌病:最近的開發平台趨勢

皮黴菌病:暫停中的計劃

皮黴菌病:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8758IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dermatomycoses - Pipeline Review, H2 2016, provides an overview of the Dermatomycoses (Infectious Disease) pipeline landscape.

Dermatophytes cause fungal infections of keratinized tissues, e.g. skin, hair and nails. The organisms belong to 3 genera, Trichophyton, Epidermophyton and Microsporum. Dermatophytes may be grouped into 3 categories based on host preference and natural habitat. Anthropophilic species predominantly infect humans, geophilic species are soil based and may infect both humans and animals, zoophilic species generally infect non-human mammals.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dermatomycoses - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dermatomycoses (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dermatomycoses (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Dermatomycoses and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.Dermatomycoses.

Dermatomycoses (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dermatomycoses (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Dermatomycoses (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dermatomycoses (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dermatomycoses (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dermatomycoses (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dermatomycoses (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dermatomycoses (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Dermatomycoses Overview
  • Therapeutics Development
    • Pipeline Products for Dermatomycoses - Overview
    • Pipeline Products for Dermatomycoses - Comparative Analysis
  • Dermatomycoses - Therapeutics under Development by Companies
  • Dermatomycoses - Therapeutics under Investigation by Universities/Institutes
  • Dermatomycoses - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Dermatomycoses - Products under Development by Companies
  • Dermatomycoses - Products under Investigation by Universities/Institutes
  • Dermatomycoses - Companies Involved in Therapeutics Development
    • Anacor Pharmaceuticals Inc
    • Biolab Farmaceutica Ltda
    • Blueberry Therapeutics Ltd
    • Daewoong Pharmaceutical Co Ltd
    • Dermala Inc
    • Helix BioMedix Inc
    • Novan Inc
    • Sol-Gel Technologies Ltd
    • TGV-Laboratories
    • Viamet Pharmaceuticals Inc
    • Vyome Biosciences Pvt Ltd
  • Dermatomycoses - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AN-2718 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BB-2603 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • clotrimazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dapaconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug for Athlete's Foot - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWP-06081 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-06 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HB-1275 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • luliconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Myc-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nitric oxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-208 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Fungal Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VT-1161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Dermatomycoses - Dormant Projects
  • Dermatomycoses - Product Development Milestones
    • Featured News & Press Releases
      • Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program
      • Jul 15, 2015: Viamet to Present at American Podiatric Medical Association 2015 Annual Scientific Meeting
      • Jul 09, 2014: Viamet Reports Additional Positive Interim Results of Phase 2 Studies of VT-1161 with Moderate to Severe Interdigital Tinea Pedis
      • Mar 12, 2014: Viamet Reports Positive Interim Results of Phase 2 Interdigital Tinea Pedis Study of VT-1161
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Dermatomycoses, H2 2016
  • Number of Products under Development for Dermatomycoses - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Dermatomycoses - Pipeline by Anacor Pharmaceuticals Inc, H2 2016
  • Dermatomycoses - Pipeline by Biolab Farmaceutica Ltda, H2 2016
  • Dermatomycoses - Pipeline by Blueberry Therapeutics Ltd, H2 2016
  • Dermatomycoses - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016
  • Dermatomycoses - Pipeline by Dermala Inc, H2 2016
  • Dermatomycoses - Pipeline by Helix BioMedix Inc, H2 2016
  • Dermatomycoses - Pipeline by Novan Inc, H2 2016
  • Dermatomycoses - Pipeline by Sol-Gel Technologies Ltd, H2 2016
  • Dermatomycoses - Pipeline by TGV-Laboratories, H2 2016
  • Dermatomycoses - Pipeline by Viamet Pharmaceuticals Inc, H2 2016
  • Dermatomycoses - Pipeline by Vyome Biosciences Pvt Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Dermatomycoses - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Dermatomycoses, H2 2016
  • Number of Products under Development for Dermatomycoses - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top